Skip to main content
SpringerLink
Log in

Drug Resistance of Non-tuberculous Mycobacteria

  • Chapter
  • First Online:
Antimicrobial Drug Resistance

  • 1920 Accesses

Abstract

Non-tuberculous Mycobacterium species (NTMs) are considered opportunistic pathogens as they cause disease in animals as well as in susceptible humans. Infections can vary from asymptomatic nodules to chronic, debilitating lung and skin infections. Depending on species- and strain-specific characteristics, some NTM infections respond readily to antibiotic treatment, while others exhibit intrinsic and non-intrinsic resistance to multiple antibiotics. Intrinsic drug resistance by NTMs may have evolutionary roots in the soil.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Chalermskulrat W, Gilbey JG, Donohue JF. Nontuberculous mycobacteria in women, young and old. Clin Chest Med. 2002;23(3):675–86.

    Article  PubMed  Google Scholar 

  2. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881–6.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182:970–6.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med. 2013;34:087–94.

    Article  Google Scholar 

  5. Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010;16:1576–83.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998–2010. Emerg Infect Dis. 2013;19:1189–891.

    Article  Google Scholar 

  7. Atkins BL, Gottlieb T. Skin and soft tissue infections caused by nontuberculous mycobacteria. Curr Opin Infect Dis. 2014;27(2):137–45.

    Article  CAS  PubMed  Google Scholar 

  8. Pilkington EF, MacArthur CJ, Beekmann SE, Polgreen PM, Winthrop KL. Treatment patterns of pediatric nontuberculous mycobacterial (NTM) cervical lymphadenitis as reported by nationwide surveys of pediatric otolaryngology and infectious disease societies. Int J Pediatr Otorhinolaryngol. 2010;74:343–6.

    Article  CAS  PubMed  Google Scholar 

  9. Pulliam JP, Vernon DD, Alexander SR, Hartstein AI, Golper TA. Nontuberculous mycobacterial peritonitis associated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1983;2:610–4.

    Article  CAS  PubMed  Google Scholar 

  10. White R, Abreo K, Flanagan R, Gadallah M, Krane K, el Shahawy M, Shakamuri S, McCoy R. Nontuberculous mycobacterial infections in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis. 1993;22:581–7.

    Article  CAS  PubMed  Google Scholar 

  11. Youmbissi JT, Malik QT, Ajit SK, Al Khursany IA, Rafi A, Karkar A. Non tuberculous mycobacterium peritonitis in continuous ambulatory peritoneal dialysis. J Nephrol. 2001;14:132–5.

    CAS  PubMed  Google Scholar 

  12. Song Y, Wu J, Yan H, Chen J. Peritoneal dialysis-associated nontuberculous mycobacterium peritonitis: a systematic review of reported cases. Nephrol Dial Transplant. 2012;27:1639–44.

    Article  PubMed  Google Scholar 

  13. Sennesael JJ, Maes VA, Pierard D, Debeukelaer SH, Verbeelen DL. Streptomycin pharmacokinetics in relapsing Mycobacterium xenopi peritonitis. Am J Nephrol. 1990;10:422–5.

    Article  CAS  PubMed  Google Scholar 

  14. Keenan N, Jeyaratnam D, Sheerin NS. Mycobacterium simiae: a previously undescribed pathogen in peritoneal dialysis peritonitis. Am J Kidney Dis. 2005;45:e75–8.

    Article  PubMed  Google Scholar 

  15. Giladi M, Lee BE, Berlin OG, Panosian CB. Peritonitis caused by Mycobacterium kansasii in a patient undergoing continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1992;19:597–9.

    Article  CAS  PubMed  Google Scholar 

  16. Hall-Stoodley L, Lappin-Scott H. Biofilm formation by the rapidly growing mycobacterial species Mycobacterium fortuitum. FEMS Microbiol Lett. 1998;168:77–84.

    Article  CAS  PubMed  Google Scholar 

  17. Schulze-Röbbecke R, Janning B, Fischeder R. Occurrence of Mycobacteria in biofilm samples. Tuber Lung Dis. 1992;73:141–4.

    Article  PubMed  Google Scholar 

  18. El Helou G, Viola GM, Hachem R, Han XY, Raad II. Rapidly growing mycobacterial bloodstream infections. Lancet Infect Dis. 2013;13:166–74.

    Article  PubMed  Google Scholar 

  19. Wallace Jr RJ, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol. 1998;52:453–90.

    Article  CAS  PubMed  Google Scholar 

  20. Kasamatsu Y, Nakagawa N, Inoue K, Kawahito Y, Hiraoka N, Yoshioka K, Yokoo S. Peritonitis due to Mycobacterium fortuitum infection following gastric cancer surgery. Intern Med. 1999;38:833–6.

    Article  CAS  PubMed  Google Scholar 

  21. Fisher EJ, Gloster Jr HM. Infection with mycobacterium abscessus after Mohs micrographic surgery in an immunocompetent patient. Dermatol Surg. 2005;31:790–4.

    Article  CAS  PubMed  Google Scholar 

  22. Dirac MA, Horan KL, Doody DR, Meschke JS, Park DR, Jackson LA, Weiss NS, Winthrop KL, Cangelosi GA. Environment or host?: A case-control study of risk factors for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;186:684–91.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Winthrop KL. Pulmonary disease due to nontuberculous mycobacteria: an epidemiologist’s view. Future Microbiol. 2010;5:343–5.

    Article  PubMed  Google Scholar 

  24. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features. Am J Respir Crit Care Med. 2010;182:977–82.

    Article  PubMed  Google Scholar 

  25. Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR, Cangelosi GA, Dirac MA, Olivier KN, Brown-Elliott BA, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med. 2012;185:231–2.

    Article  CAS  PubMed  Google Scholar 

  26. Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, Reacher M, Haworth CS, Curran MD, Harris SR, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. The Lancet. 2004;381:1551–60.

    Article  CAS  Google Scholar 

  27. Harris KA, Kenna DT, Blauwendraat C, Hartley JC, Turton JF, Aurora P, Dixon GLJ. Molecular fingerprinting of Mycobacterium abscessus strains in a cohort of pediatric cystic fibrosis patients. J Clin Microbiol. 2012;50:1758–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Huang WC, Chiou CS, Chen JH, Shen GH. Molecular epidemiology of Mycobacterium abscessus infections in a subtropical chronic ventilatory setting. J Med Microbiol. 2010;59:1203–11.

    Article  CAS  PubMed  Google Scholar 

  29. Davidson RM, Hasan NA, de Moura VCN, Duarte RS, Jackson M, Strong M. Phylogenomics of Brazilian epidemic isolates of Mycobacterium abscessus subsp. bolletii reveals relationships of global outbreak strains. Infection. Infect Genet Evol. 2013;20:292–7.

    Article  PubMed  Google Scholar 

  30. Dirac MA, Weigel KM, Yakrus MA, Becker AL, Chen HL, Fridley G, Sikora A, Speake C, Hilborn ED, Pfaller S, et al. Shared Mycobacterium avium genotypes observed among unlinked clinical and environmental isolates. Appl Environ Microbiol. 2013;79:5601–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Horan KL, Freeman R, Weigel K, Semret M, Pfaller S, Covert TC, van Soolingen D, Leao SC, Behr MA, Cangelosi GA. Isolation of the genome sequence strain Mycobacterium avium 104 from multiple patients over a 17-year period. J Clin Microbiol. 2006;44:783–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.

    Article  CAS  PubMed  Google Scholar 

  33. Hoefsloot W, van Ingen J, Andrejak C, Ȁngeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42:1604–13.

    Article  PubMed  Google Scholar 

  34. Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL, Tomashefski J, Knowles MR. Nontuberculous mycobacteria. II: Nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med. 2003;167:835–40.

    Article  PubMed  Google Scholar 

  35. Wickremasinghe M, Ozerovitch LJ, Davies G, Wodehouse T, Chadwick MV, Abdallah S, Shah P, Wilson R. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax. 2005;60:1045–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. American Lung Association and the American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156:S1–25.

    Article  Google Scholar 

  37. Holland SM, Eisenstein EM, Kuhns DB, Turner ML, Fleisher TA, Strober W, Gallin JI. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med. 1994;330:1348–55.

    Article  CAS  PubMed  Google Scholar 

  38. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis. 2004;38:1428–39.

    Article  PubMed  Google Scholar 

  39. Jouanguy E, Lamhamedi-Cherradi S, Lammas D, Dorman SE, Fondaneche MC, Dupuis S, Doffinger R, Altare F, Girdlestone J, Emile JF, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet. 1999;21:370–8.

    Article  CAS  PubMed  Google Scholar 

  40. O’Connell E, Rosen L, LaRue R, Fabre V, Melia M, Auwaerter P, Holland S, Browne S. The first US domestic report of disseminated Mycobacterium avium complex and anti-interferon-γ autoantibodies. J Clin Immunol. 2014;34(8):928–32.

    Article  PubMed  CAS  Google Scholar 

  41. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, Drysdale P, Jouanguy E, Doffinger R, Bernaudin F, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 1998;280:1432–5.

    Article  CAS  PubMed  Google Scholar 

  42. de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, Breda Vriesman PJ, Kabel PJ, Draaisma JM, van Dissel JT, Kroon FP, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 1998;280:1435–8.

    Article  PubMed  Google Scholar 

  43. Winthrop KL, Iseman M. Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy. Nat Rev Rheumatol. 2013;9:524–31.

    Article  PubMed  Google Scholar 

  44. Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. Nontuberculous Mycobacteria infections and anti-tumour necrosis factor-alpha therapy. Emerg Infect Dis. 2009;15:1556–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Yoo JW, Jo KW, Kang BH, Kim MY, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, Kim KJ, et al. Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy. Eur Respir J. 2014;44(5):1289–95.

    Article  CAS  PubMed  Google Scholar 

  46. Liao CH, Chen MY, Hsieh SM, Sheng WH, Hung CC, Chang SC. Discontinuation of secondary prophylaxis in AIDS patients with disseminated non-tuberculous mycobacteria infection. J Microbiol Immunol Infect. 2004;37:50–6.

    PubMed  Google Scholar 

  47. Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, Lindeboom R, Prins JM. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis. 2007;44:1057–64.

    Article  CAS  PubMed  Google Scholar 

  48. Ballarino GJ, Olivier KN, Claypool RJ, Holland SM, Prevots DR. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med. 2009;103:1448–55.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann ATS. 2013;11:9–16.

    Article  Google Scholar 

  50. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, Nelson K, Caccitolo J, Alvarez J, Shepherd S, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174:928–34.

    Article  CAS  PubMed  Google Scholar 

  51. Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother. 1993;37:2364–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Gardner EM, Burman WJ, DeGroote MA, Hildred G, Pace NR. Conventional and molecular epidemiology of macrolide resistance among new Mycobacterium avium complex isolates recovered from HIV-infected patients. Clin Infect Dis. 2005;41:1041–4.

    Article  CAS  PubMed  Google Scholar 

  53. Santin M, Alcaide F. Mycobacterium kansasii disease among patients infected with human immunodeficiency virus type 1: improved prognosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis. 2003;7:673–7.

    CAS  PubMed  Google Scholar 

  54. Marras TK, Morris A, Gonzalez LC, Daley CL. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med. 2004;170:793–8.

    Article  PubMed  Google Scholar 

  55. Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis. 2004;4:557–65.

    Article  PubMed  Google Scholar 

  56. Wallace J, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE. MAcrolide/azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014;146:276–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis. 1998;27:1278–85.

    Article  CAS  PubMed  Google Scholar 

  58. Mitchell JD, Bishop A, Cafaro A, Weyant MJ, Pomerantz M. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg. 2008;85:1887–93.

    Article  PubMed  Google Scholar 

  59. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2004;53:1–112.

    PubMed  Google Scholar 

  60. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51:1–52.

    Google Scholar 

  61. Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, Hogg R, O’Shaughnessy M, Montaner J. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis. 2005;41:1483–97.

    Article  PubMed  Google Scholar 

  62. Hallstrand TS, Ochs HD, Zhu Q, Liles WC. Inhaled IFN-gamma for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-gamma deficiency. Eur Respir J. 2004;24:367–70.

    Article  CAS  PubMed  Google Scholar 

  63. Wallace Jr RJ, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2001;45:764–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Guna R, Munoz C, Dominguez V, Garcia-Garcia A, Galvez J, Julian-Ortiz JV, Borras R. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother. 2005;55:950–3.

    Article  CAS  PubMed  Google Scholar 

  65. Brown-Elliott BA, Crist CJ, Mann LB, Wilson RW, Wallace Jr RJ. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2003;47:1736–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Alcaide F, Calatayud L, Santin M, Martin R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother. 2004;48:4562–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Brown-Elliott BA, Wallace Jr RJ, Blinkhorn R, Crist CJ, Mann LB. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis. 2001;33:1433–4.

    Article  CAS  PubMed  Google Scholar 

  68. Rastogi N, Goh KS, Bryskier A, Devallois A. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother. 1996;40:2483–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Jo KW, Kim S, Lee JY, Lee SD, Kim WS, Kim DS, Shim TS. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy. J Infect Chemother. 2014;20:602–6.

    Article  CAS  PubMed  Google Scholar 

  70. Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace Jr RJ. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2005;172:250–3.

    Article  PubMed  Google Scholar 

  71. Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, Korvick JA, Heifets L, Child CC, Lederman MM, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis. 2000;181:1289–97.

    Article  CAS  PubMed  Google Scholar 

  72. Midoneck SR, Etingin OR. Clarithromycin-related toxic effects of digoxin. N Engl J Med. 1995;333:1505.

    Article  CAS  PubMed  Google Scholar 

  73. Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, Benson CA, Meek K, Siepman N, Craft JC. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS. 1997;11:311–7.

    Article  CAS  PubMed  Google Scholar 

  74. Miguez-Burbano MJ, Flores M, Ashkin D, Rodriguez A, Granada AM, Quintero N, Pitchenik A. Non-tuberculous mycobacteria disease as a cause of hospitalization in HIV-infected subjects. Int J Infect Dis. 2006;10:47–55.

    Article  PubMed  Google Scholar 

  75. Falkinham JOI, Norton CD, LeChevallier MW. Factors influencing numbers of Mycobacterium avium, Mycobacterium intracellulare, and other mycobacteria in drinking water distribution systems. Appl Environ Microbiol. 2001;67:1225–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Falkinham JO 3rd. Sources, transmission, and exposure of M. avium. In: Bartram J, Rees G, editors. Pathogenic mycobacteria in water World Health Organization—U.S. Environmental Protection Agency, Geneva. 2003.

    Google Scholar 

  77. Falkinham III JO. Factors influencing the chlorine susceptibility of Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum. Appl Environ Microbiol. 2003;69:5685–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Taylor RH, Falkinham JOI, Norton CD, LeChevallier MW. Chlorine, chloramines, chlorine dioxide, and ozone susceptibility of Mycobacterium avium. Appl Environ Microbiol. 2000;66:1702–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Shin GA, Lee JK, Freeman R, Cangelosi GA. Inactivation of Mycobacterium avium complex by UV irradiation. Appl Environ Microbiol. 2008;74:7067–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Bolan G, Reingold AL, Carson LA, Silcox VA, Woodley CL, Hayes PS, Hightower AW, McFarland L, Brown III JW, Petersen NJ, et al. Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers. J Infect Dis. 1985;152:1013–9.

    Article  CAS  PubMed  Google Scholar 

  81. Heifets L, Cangelosi GA. Antibiotic susceptibility testing of Mycobacterium tuberculosis—a neglected problem at the turn of the century. Int J Tuberc Lung Dis. 2002;3:564–81.

    Google Scholar 

  82. Morris S, Gai BH, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis. 1995;171:954–60.

    Article  CAS  PubMed  Google Scholar 

  83. Somoskovi A, Parsons L, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res. 2001;2:164–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Garcia de Viedma D. Rapid detection of resistance in Mycobacterium tuberculosis: a review discussing molecular approaches. Clin Microbiol Infect. 2003;9:349–59.

    Article  CAS  PubMed  Google Scholar 

  85. Klein JL, Brown TJ, French GL. Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Antimicrob Agents Chemother. 2001;45:3056–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Williams DL, Waguespack C, Eisenach K, Crawford JT, Portaels F, Salfinger M, Nolan AC, Sticht-Groh V, Gillis TP. Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother. 1994;38:2380–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Burman WJ, Stone BL, Brown BA, Richard J, Bottger EC. AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin. Diagn Microbiol Infect Dis. 1998;31:369–71.

    Article  CAS  PubMed  Google Scholar 

  88. Vemulapalli RK, Cantey JR, Steed LL, Knapp TL, Thielman NM. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection: case report and literature review. J Infect. 2001;43:163–8.

    Article  CAS  PubMed  Google Scholar 

  89. Wallace Jr RJ, Meier A, Brown BA, Zhang Y, Sander P, Onyi GO, Bottger EC. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother. 1996;40:1676–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Nash KA, Inderlied CB. Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex [published erratum appears in Antimicrob Agents Chemother 1996;40(10):2442]. Antimicrob Agents Chemother. 1996;40:1748–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Jamal MA, Maeda S, Nakata N, Kai M, Fukuchi K, Kashiwabara Y. Molecular basis of clarithromycin-resistance in Mycobacterium avium-intracellulare complex. Tuber Lung Dis. 2000;80:1–4.

    Article  CAS  PubMed  Google Scholar 

  92. Meier A, Heifets L, Wallace RJ, Zhang Y, Brown BA, Sander P, Bottger EC. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis. 1996;174:354–60.

    Article  CAS  PubMed  Google Scholar 

  93. Cangelosi GA, Palermo CO, Bermudez LE. Phenotypic consequences of red-white colony type variation in Mycobacterium avium. Microbiology. 2001;147:527–33.

    Article  CAS  PubMed  Google Scholar 

  94. Mukherjee S, Petrofsky M, Yaraei K, Bermudez LE, Cangelosi GA. The white morphotype of Mycobacterium avium-intracellulare is common in infected humans and virulent in infection models. J Infect Dis. 2001;184:1480–4.

    Article  CAS  PubMed  Google Scholar 

  95. Obata S, Zwolska Z, Toyota E, Kudo K, Nakamura A, Sawai T, Kuratsuji T, Kirikae T. Association of rpoB mutations with rifampicin resistance in Mycobacterium avium. Int J Antimicrob Agents. 2006;27:32–9.

    Article  CAS  PubMed  Google Scholar 

  96. Portillo-Gomez L, Nair J, Rouse DA, Morris SL. The absence of genetic markers for streptomycin and rifampicin resistance in Mycobacterium avium complex strains. J Antimicrob Chemother. 1995;36:1049–53.

    Article  CAS  PubMed  Google Scholar 

  97. Rastogi N, Goh KS, Clavel-Seres S. Stazyme, a mycobacteriolytic preparation from a Staphylococcus strain, is able to break the permeability barrier in multiple drug resistant Mycobacterium avium. FEMS Immunol Med Microbiol. 1997;19:297–305.

    Article  CAS  PubMed  Google Scholar 

  98. Jarlier V, Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett. 1994;123:11–8.

    Article  CAS  PubMed  Google Scholar 

  99. Nikaido H, Jarlier V. Permeability of the mycobacterial cell wall. Res Microbiol. 1991;142:437–43.

    Article  CAS  PubMed  Google Scholar 

  100. Cangelosi GA, Do JS, Freeman R, Bennett JG, Semret M, Behr MA. The two-component regulatory system mtrAB is required for morphotypic multidrug resistance in Mycobacterium avium. Antimicrob Agents Chemother. 2006;50:461–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Philalay JS, Palermo CO, Hauge KA, Rustad TR, Cangelosi GA. Genes required for intrinsic multidrug resistance in Mycobacterium avium. Antimicrob Agents Chemother. 2004;48:3412–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Mailaender C, Reiling N, Engelhardt H, Bossmann S, Ehlers S, Niederweis M. The MspA porin promotes growth and increases antibiotic susceptibility of both Mycobacterium bovis BCG and Mycobacterium tuberculosis. Microbiology. 2004;150:853–64.

    Article  CAS  PubMed  Google Scholar 

  103. Ibrahim P, Whiteley AS, Barer MR. SYTO16 labelling and flow cytometry of Mycobacterium avium. Lett Appl Microbiol. 1997;25:437–41.

    Article  CAS  PubMed  Google Scholar 

  104. Nguyen HT, Wolff KA, Cartabuke RH, Ogwang S, Nguyen L. A lipoprotein modulates activity of the MtrAB two-component system to provide intrinsic multidrug resistance, cytokinetic control and cell wall homeostasis in Mycobacterium. Mol Microbiol. 2010;76:348–64.

    Article  CAS  PubMed  Google Scholar 

  105. Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, Warren RM, Streicher EM, Calver A, Sloutsky A, et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet. 2013;45:1183–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Rüger K, Hampel A, Billig S, Rücker N, Suerbaum S, Bange FC. Characterization of rough and smooth morphotypes of Mycobacterium abscessus isolates from clinical specimens. J Clin Microbiol. 2014;52:244–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  107. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 2012;67:810–8.

    Article  CAS  PubMed  Google Scholar 

  108. Nguyen L, Thompson CJ. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol. 2006;14:304–12.

    Article  CAS  PubMed  Google Scholar 

  109. Buriankova K, Doucet-Populaire F, Dorson O, Gondran A, Ghnassia JC, Weiser J, Pernodet JL. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother. 2004;48:143–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Morris RP, Nguyen L, Gatfield J, Visconti K, Nguyen K, Schnappinger D, Ehrt S, Liu Y, Heifets L, Pieters J, et al. Ancestral antibiotic resistance in Mycobacterium tuberculosis. PNAS. 2005;102:12200–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Segura C, Salvado M, Collado I, Chaves J, Coira A. Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 1998;42:1524–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  112. Voladri RK, Lakey DL, Hennigan SH, Menzies BE, Edwards KM, Kernodle DS. Recombinant Expression and Characterization of the Major beta -Lactamase of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998;42:1375.

    CAS  PubMed  PubMed Central  Google Scholar 

  113. Benson CA, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, Inderlied CB, Flexner C, Neidig J, Chaisson R, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37:1234–43.

    Article  CAS  PubMed  Google Scholar 

  114. Luong A, McClay JE, Jafri HS, Brown O. Antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis. Laryngoscope. 2005;115:1746–51.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Virginia Mason Medical Center, Seattle, WA, USA

    Kathleen L. Horan M.D.

  2. Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, USA

    Gerard A. Cangelosi Ph.D.

Authors
  1. Kathleen L. Horan M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerard A. Cangelosi Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen L. Horan M.D. .

Editor information

Editors and Affiliations

  1. Treiber Therapeutics, Cambridge, Massachusetts, USA

    Douglas L. Mayers

  2. Wayne State University School of Medicine, Detroit Medical Center, Detroit, Michigan, USA

    Jack D. Sobel

  3. Canada Research Chair in Antimicrobial Resistance, Centre de recherche en Infectiologie, University of Laval, Quebec City, Canada

    Marc Ouellette

  4. Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA

    Keith S. Kaye

  5. Infection Control and Prevention Unit of Infectious Diseases, Assaf Harofeh Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

    Dror Marchaim

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Horan, K.L., Cangelosi, G.A. (2017). Drug Resistance of Non-tuberculous Mycobacteria. In: Mayers, D., Sobel, J., Ouellette, M., Kaye, K., Marchaim, D. (eds) Antimicrobial Drug Resistance. Springer, Cham. https://doi.org/10.1007/978-3-319-47266-9_17

Download citation

Publish with us

Policies and ethics

Search

Navigation